Boehringer Ingelheim has bought rights to preclinical technology aimed at fibro-inflammatory diseases including the fatty liver disease known as NASH, a prime target for many pharma compani
Dutch biotech NorthSea Therapeutics has raised around $40 million in a series B financing round to help it develop novel strategies to treat the fatty liver disease known as NASH.<
